Thomas Perone
Compliance Officer at OVID THERAPEUTICS INC.
Net worth: 38 697 $ as of 29/04/2024
Profile
Thomas M.
Perone is currently the Secretary & Chief Compliance Officer at Ovid Therapeutics, Inc. He previously worked as the Senior Director-Legal at ImClone LLC from 2001 to 2006 and as the Vice President & Assistant Corporate Secretary at Celgene Corp.
from 2006 to 2018.
Prior to that, he was an Associate Attorney at Proskauer Rose LLC.
Mr. Perone completed his undergraduate degree at Rutgers State University of New Jersey in 1986.
He then earned an MBA from Fairleigh Dickinson University in 1993 and a graduate degree from Seton Hall University School of Law in 1997.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
OVID THERAPEUTICS INC.
0.02% | 08/04/2024 | 12,942 ( 0.02% ) | 38 697 $ | 29/04/2024 |
Thomas Perone active positions
| Companies | Position | Start |
|---|---|---|
| OVID THERAPEUTICS INC. | Compliance Officer | - |
Former positions of Thomas Perone
| Companies | Position | End |
|---|---|---|
| CELGENE | General Counsel | - |
ImClone LLC
 ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | General Counsel | 31/03/2006 |
| Proskauer Rose LLC | Corporate Officer/Principal | - |
Training of Thomas Perone
| Fairleigh Dickinson University | Masters Business Admin |
| Seton Hall University School of Law | Graduate Degree |
| Rutgers State University of New Jersey | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| OVID THERAPEUTICS INC. | Health Technology |
| Private companies | 3 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
ImClone LLC
ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | Health Technology |
| Proskauer Rose LLC |
- Stock Market
- Insiders
- Thomas Perone
